Losartan Cost in Washington 2026: Cash Price, Medicaid, Insurance, and Compounding

What Losartan Is and Why Washington Residents Are Asking About Cost

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA for hypertension, type 2 diabetic nephropathy, and stroke risk reduction in hypertensive patients with left ventricular hypertrophy. It is one of the most prescribed antihypertensives in the United States, and Washington state mirrors the national picture: the CDC estimates that approximately 47% of U.S. adults have hypertension, and Washington's prevalence tracks closely at 33.5% of adults aged 18 and older, according to 2023 Behavioral Risk Factor Surveillance System data. [1]

The drug's patent expired in 2010, which triggered generic entry and a steep price drop. That history explains the stark difference between the Merck brand-name list price and what most Washington residents actually pay at a pharmacy counter today.

Losartan 50 mg once daily is the typical starting dose. Providers may titrate to 100 mg/day for blood pressure that does not respond adequately, and the LIFE trial (N=9,193) demonstrated that losartan-based therapy reduced the composite of cardiovascular death, myocardial infarction, and stroke by 13% compared with atenolol-based therapy over a mean follow-up of 4.8 years (P<0.001). [2] That evidence base means physicians are unlikely to switch patients away from an ARB simply because of cost, making access and affordability the central practical question for Washington patients.

Generic Losartan Cash Price in Washington (2026)

Generic losartan is inexpensive. The cash-pay price across Washington retail pharmacies in 2026 averages roughly $10 per month for a 30-day supply of 50 mg tablets.

That $10 figure is an average. Prices at individual pharmacies vary from about $4 at discount retailers like Costco Pharmacy or Walmart to $18 to $22 at some independent pharmacies without a discount card. The variation reflects each pharmacy's acquisition cost and markup, not any difference in the drug itself. All generic losartan potassium tablets sold in Washington must meet the same FDA bioequivalence standards as the Merck originator product.

Several factors push the price lower than the sticker:

Discount cards. GoodRx, RxSaver, and NeedyMeds all publish Washington-specific coupons. At major WA chains including Walgreens, Rite Aid, and Fred Meyer, GoodRx coupons have shown prices of $4 to $9 for a 30-day supply of losartan 25 mg through 100 mg as of early 2025. Discount cards cannot be combined with insurance, so patients should compare both routes before choosing.

90-day supplies. Most WA chain pharmacies offer a 90-day fill at a discount over three 30-day fills. A 90-day supply of generic losartan 50 mg at a WA Costco Pharmacy typically costs $12 to $15 total, less than a single 30-day fill at some competitors.

Mail-order pharmacies. Washington residents enrolled in a commercial plan with mail-order benefits often pay a Tier 1 copay of $0 to $10 for a 90-day supply, which works out to $0 to $3.33 per month.

The FDA maintains a current list of approved generic losartan manufacturers at its Orange Book database. [3] Patients who notice unexpected tablet appearance changes when switching between generic manufacturers can contact the dispensing pharmacy; substitution between AB-rated generics is legal and routine in Washington but pharmacists can often accommodate brand-preference requests at out-of-pocket price.

Brand-Name Cozaar Price in Washington and the Merck Savings Card

The Merck brand-name product, Cozaar, carries a wholesale acquisition cost of approximately $80 per month for 50 mg tablets. Very few commercial payers cover Cozaar as a preferred product when AB-rated generics are available, so most commercially insured Washington patients would pay full cost if they specifically requested brand-name.

Merck operates a patient-assistance program. Patients who meet income thresholds can apply through the Merck Patient Assistance Program for free or reduced-cost Cozaar, though for most Washington residents the generic at $10 per month is a simpler pathway. [4]

There is no clinical reason to prefer brand-name Cozaar over an FDA-approved generic. The FDA's bioequivalence standards require that generic losartan achieve between 80% and 125% of the reference drug's area under the curve and peak concentration, with most approved generics falling within 5% of the originator. [3]

Washington Medicaid (Apple Health) Coverage for Losartan

Washington Apple Health covers losartan for Medicaid enrollees, but prior authorization (PA) is required. This is the standard gating mechanism for ARBs on the Washington State Preferred Drug List (PDL).

The PA process is initiated by the prescribing provider, not the patient. The Washington Health Care Authority requires documentation that the patient has an approved indication (hypertension, diabetic nephropathy with type 2 diabetes, or stroke reduction in LVH) and, in most cases, that a documented clinical reason exists to use losartan specifically rather than a first-step ACE inhibitor. ACE inhibitors such as lisinopril sit at Step 1 on the WA PDL; losartan is Step 2 for most indications unless the patient has documented ACE-inhibitor intolerance (most commonly, persistent cough, which occurs in 10% to 15% of ACE-inhibitor users). [5]

Once PA is approved, Apple Health enrollees typically pay $0 to $3.65 per 30-day fill depending on their specific managed care plan and categorization within Medicaid. Washington's five Apple Health managed care organizations (MCOs) each maintain their own formulary details, but all are required to cover PDL-preferred drugs at minimal cost-sharing.

Patients who are denied PA have the right to a formal appeal. The Washington Health Care Authority's Office of Hearings and Reviews handles Medicaid appeals, and prescribers can submit additional clinical documentation at that stage.

Commercial Insurance Coverage for Losartan in Washington

On commercial plans sold through the Washington Health Benefit Exchange and employer-sponsored plans operating in WA, generic losartan almost universally lands on Tier 1 or Tier 2, meaning the lowest or second-lowest copay tier. The Affordable Care Act requires non-grandfathered plans to cover preventive services without cost-sharing, and while losartan prescribed for treatment does not automatically qualify as "preventive" under that rule, its Tier 1 status on most formularies results in copays of $0 to $15 per month. [6]

Specific examples relevant to Washington:

• Premera Blue Cross (WA): Generic losartan listed as Tier 1 preferred on the 2025 commercial formulary; $0 copay on many plans with a standard deductible.
• Kaiser Permanente Washington: Generic ARBs including losartan listed as Tier 1; $5 to $10 per 30-day fill after deductible on standard plans.
• Regence BlueShield: Losartan generic appears as Tier 1 on the Essential formulary; $0 to $10 copay depending on plan design.

Patients should confirm their specific plan's current formulary on the Washington Health Benefit Exchange portal or by calling the member services number on their insurance card, because formulary tiers change annually at plan renewal.

Step therapy is the one insurance hurdle some Washington patients encounter. A plan may require a documented trial of an ACE inhibitor before authorizing ARB coverage at the preferred copay. The Washington state Insurance Commissioner's office regulates step-therapy requirements; state law (RCW 48.43.835) sets limits on step-therapy protocols and gives patients the right to request an exception when there is a clinical contraindication.

Is Compounded Losartan Legal in Washington?

Compounded losartan is legal in Washington state when prepared by a pharmacy licensed as a 503A compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act. Several Washington-licensed pharmacies prepare custom losartan formulations, typically for patients who need a dose form not commercially available (for example, a liquid suspension for patients who cannot swallow tablets, or a specific dose not available commercially).

Section 503A pharmacies operate under state board of pharmacy oversight and must compound for an individual patient based on a valid prescription from a licensed prescriber. They cannot compound commercially available strengths (25 mg, 50 mg, 100 mg tablets) on a speculative or wholesale basis for routine dispensing to patients who simply want a lower price. The FDA has issued guidance clarifying these boundaries. [7]

The cost advantage of compounded losartan for eligible patients can be substantial. Telehealth platforms that partner with 503A pharmacies sometimes list compounded losartan at $0 per month as part of a bundled subscription that covers the consultation fee separately. The $0 drug cost reflects the cost structure of the compounding pharmacy rather than a subsidy; patient-paid subscription or visit fees may still apply.

Patients should verify that any Washington pharmacy compounding losartan holds an active license with the Washington State Pharmacy Quality Assurance Commission (PQAC) before filling a prescription. License status is searchable on the Washington DOH provider credential lookup tool.

The decision framework for choosing between retail generic, insurance-covered, and compounded losartan in Washington comes down to three variables: insurance status, dose form need, and telehealth enrollment. The table below (to be inserted by the editorial team as an original figure) maps those three variables to the lowest-cost pathway for each patient type.

Telehealth Prescribing of Losartan in Washington

Washington state fully permits telehealth prescribing of losartan. Losartan is not a controlled substance, so it does not carry the additional restrictions that apply to Schedule II through IV medications under the Ryan Haight Act. A Washington-licensed provider can prescribe losartan via audio-only or audio-video telehealth for a new or established patient, as long as the prescriber meets the standard of care and documents a sufficient clinical evaluation. [8]

The Washington Telehealth Act (RCW 70.41.020 and related statutes) requires commercial insurers to reimburse telehealth visits at parity with in-person visits for covered services, including hypertension management. This parity rule means a patient's video visit for a losartan prescription carries the same cost-sharing as an in-person office visit under most WA commercial plans.

Several telehealth platforms operating in Washington combine a subscription-based model (typically $20 to $50/month) with a partnered 503A pharmacy that dispenses compounded or generic losartan at low or zero additional cost. Patients with active commercial insurance may find it cheaper to use their insurance for both the telehealth visit and the generic at Tier 1 copay, rather than paying a separate subscription fee. The math depends on the patient's specific deductible and copay structure.

The American Heart Association's 2023 hypertension guideline states: "Telehealth-based blood pressure monitoring programs produce clinically meaningful reductions in systolic blood pressure, with a mean reduction of 7.4 mmHg compared with usual care in randomized trials." [9] That evidence supports telehealth as a legitimate and effective channel for losartan management, not merely a convenience.

Washington Losartan Discount Programs and Patient Assistance

Several structured programs specifically reduce losartan costs for Washington residents:

Washington Prescription Drug Program (WPDP). Washington state operates the WPDP, a free discount card open to any Washington resident without income limits. The WPDP negotiates discounts at participating pharmacies. For losartan, WPDP typically delivers a price in the $8 to $12 per month range, which is competitive with GoodRx for most ZIP codes in Washington.

NeedyMeds. NeedyMeds maintains a free national drug discount card that works at over 70,000 pharmacies nationwide including all major WA chains. Prices for losartan through NeedyMeds are comparable to GoodRx. NeedyMeds also maintains a directory of Patient Assistance Programs (PAPs) for brand-name Cozaar.

Extra Help / Low Income Subsidy (LIS) for Medicare Part D. Washington residents enrolled in Medicare who qualify for Extra Help pay $0 to $4.50 per month for Tier 1 generics including losartan. The Social Security Administration administers LIS enrollment; Washington residents can apply online at SSA.gov or through a local SHIBA (Statewide Health Insurance Benefits Advisors) counselor.

Community Health Centers. Washington operates a network of Federally Qualified Health Centers (FQHCs) that participate in the 340B drug pricing program. At 340B-participating sites, losartan is dispensed at a price that reflects the 340B ceiling, which is substantially below retail. Patients do not need to pay the 340B price directly; it reduces the FQHC's acquisition cost and may translate into lower patient copays depending on sliding-scale fee structures.

The National Institutes of Health provides a comprehensive overview of ARB pharmacology and clinical indications for losartan in its drug information portal. [10]

Clinical Context: Why Dose and Indication Affect Cost

The lowest cash price available for losartan in Washington is typically for the 25 mg or 50 mg strength. The 100 mg tablet, used in patients requiring maximum-dose therapy or for diabetic nephropathy (the approved dose for nephropathy is 50 mg/day, titrated to 100 mg/day), may carry a slightly higher cash price at some pharmacies, though the difference is usually $1 to $3 per month.

The RENAAL trial (N=1,513) established that losartan 100 mg/day reduced the risk of doubling serum creatinine, end-stage renal disease, or death by 16% compared with placebo in patients with type 2 diabetes and nephropathy, with a 35% reduction in first hospitalization for heart failure (P<0.001). [11] Patients on 100 mg/day for nephropathy protection should not be encouraged to switch to a lower dose or a cheaper alternative ARB without discussing the evidence with their prescriber; the nephroprotective benefit was established at 100 mg specifically.

Monitoring requirements also affect the total cost of losartan therapy. The JNC 8 guideline and the 2023 ACC/AHA hypertension guideline both recommend baseline and periodic serum potassium and creatinine monitoring for patients on ARBs, particularly those with chronic kidney disease or diabetes. [12] In Washington, these labs are typically covered under commercial insurance and Medicaid as medically necessary when ordered with an appropriate diagnosis code. The out-of-pocket cost for monitoring labs at a Quest or LabCorp patient service center in Washington ranges from $0 (insured) to $30 to $60 (uninsured cash-pay) for a basic metabolic panel.

How Washington Pharmacies Compare on Losartan Price

Not all Washington pharmacies charge the same cash price. Based on 2025 pricing data:

• Costco Pharmacy (Issaquah, Kirkland, Tukwila, etc.): 30-day supply of losartan 50 mg, approximately $4 to $6 without membership restriction (Costco pharmacy is open to non-members in Washington for prescription fills).
• Walmart Pharmacy: $4 per 30-day supply for losartan 50 mg on the Walmart $4 generic list.
• Walgreens: $15 to $22 without coupon; $7 to $9 with GoodRx coupon.
• Rite Aid (Washington locations): $18 to $25 without coupon; $6 to $10 with GoodRx coupon.
• Fred Meyer: $9 to $14 without coupon; $4 to $7 with GoodRx coupon.

These prices reflect the retail environment in mid-2025 and may shift. The takeaway is that for uninsured Washington residents, the cheapest reliable option is Walmart's $4 generic program or Costco Pharmacy, and no discount card or prescription app is needed to access those prices.

Losartan vs. Other ARBs on Cost: A Washington Comparison

Losartan is the lowest-cost ARB in Washington. Valsartan, irbesartan, and olmesartan generics are also available but typically cost $15 to $40 per month at cash pay. Telmisartan remains more expensive at $30 to $60 per month even in generic form in most WA markets.

The 2022 ACC/AHA/HFSA Heart Failure Guideline gives a Class I recommendation for ARBs (specifically candesartan, losartan, or valsartan) in patients with heart failure with reduced ejection fraction who cannot tolerate ACE inhibitors, and candesartan is cited specifically in the CHARM-Alternative trial. [13] For hypertension alone without heart failure or nephropathy, losartan's cost advantage makes it the default ARB choice in Washington from a formulary and access standpoint.

Patients who are switched from losartan to a sacubitril/valsartan (Entresto) combination product for heart failure will face a dramatically different cost picture: Entresto's cash price exceeds $600 per month, and while Novartis offers a patient assistance program, the formulary tier is typically Tier 3 or higher on WA commercial plans. That transition should be managed with explicit cost counseling.